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Abstract
Structural variants of the Mannose Binding Lectin (MBL) cause quantitative and qualitative functional deficiencies, which are
associated with various patterns of susceptibility to infectious diseases and other disorders. We determined genetic MBL
variants in 2010 Ghanaian patients with pulmonary tuberculosis (TB) and 2346 controls and characterized the mycobacterial
isolates of the patients. Assuming a recessive mode of inheritance, we found a protective association between TB and the
MBL2 G57E variant (odds ratio 0.60, confidence interval 0.4–0.9, P 0.008) and the corresponding LYQC haplotype (Pcorrected
0.007) which applied, however, only to TB caused by M. africanum but not to TB caused by M. tuberculosis. In vitro, M.
africanum isolates bound recombinant human MBL more efficiently than did isolates of M. tuberculosis. We conclude that
MBL binding may facilitate the uptake of M. africanum by macrophages, thereby promoting infection and that selection by
TB may have favoured the spread of functional MBL deficiencies in regions endemic for M. africanum.
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Introduction
Mannose-binding lectin (MBL) is a plasma opsonin of the
collectin family. Its monomer consists of a 228-amino-acid
polypeptide chain. Through extended alpha-helical structures it
forms homotrimers which commonly associate to higher oligo-
mers, preferentially hexamers. MBL plays a complex role in the
immune response, in particular at primary contact with microbial
pathogens but also in the later course infections. In a calcium-
dependent fashion, it binds to carbohydrate structures on the
surfaces of a wide range of microorganisms [1] and promotes
phagocytosis either directly through a yet undefined receptor or
indirectly via activation of the lectin pathway of complement.
Human MBL is encoded by the MBL2 gene on chromosome 10
(10q11.2–q21; OMIM 154545), which comprises four exons. Its
transcription is influenced by common promoter polymorphisms
at nucleotide positions 2550 (rs11003125, allele H.L), 2221
(rs7096206, allele Y.X) and +4 (rs7095891, allele P.Q) [2].
Among these, the X allele (2221G) has a pronounced down-
regulating effect. Of particular interest is a small cluster of
structural variants at codon positions 52, 54 and 57 located in
exon 1. The wild-type is designated allele A, and polymorphisms
R52C (rs5030737), G54D (rs1800450) and G57E (rs1800451) are
addressed as alleles D, B and C, respectively [3]. By disrupting the
alpha-helical structure of the monomer they impede oligomeriza-
tion. Heterozygous and homozygous variants result in partial or
virtually complete functional deficiencies, respectively, whereby
alleles B and C have stronger effects than allele D [4].
MBL2 variants are quite frequent, although unevenly distribut-
ed in human populations [3]. Allele B is extremely rare in West
Africa but occur at frequencies of 0.14, 0.25 and 0.50 in
Caucasians, Asians and indigenous South Americans, respectively.
In contrast, allele C is rare among Caucasians but common in sub-
Saharan Africa, where it reaches frequencies of 0.20 and higher.
Allele D in general is rather uncommon and appears to be largely
restricted to North Africans and Caucasians. The high allele
frequencies in certain populations suggested that functional MBL
deficiencies might confer some biological advantage [5].
The genetic MBL2 variants have been found to be associated
with differences in susceptibility to a variety of infectious diseases
and autoimmune disorders [4,6]. Studies on human TB yielded
partly inconsistent data. No significant associations were found in
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negatively associated with pulmonary disease [7]. Similarly, the
heterozygous occurrence of the B allele was found negatively
associated with tuberculous meningitis in South Africa [8], and the
B allele was also less frequent in Afro-American pulmonary TB
cases than in controls [9]. In another study, however, the
frequency of the B allele was significantly higher in Afro-American
TB patients than in controls [9]. In the same study, no differences
between cases and controls were seen in individuals of Caucasian
and Hispanic origin while a further study found MBL low-
producing haplotypes more frequent in Caucasian TB patients
than among controls [10]. In South India, a positive association of
the B allele with disease was observed [11], and likewise, the C
allele was found to be more frequent among HIV-positive TB
patients than among HIV-negative controls in Malawi [12].
Finally, no association of MBL2 variants with TB was found in a
Han Chinese population [13].
Evidence has been presented indicating that genetic variants of
the pathogen may also significantly contribute to both acquisition
and clinical progression of TB [14–17]. Mycobacteria causing
‘‘typical’’ TB have been summed up in the M. tuberculosis complex
(MTBC), and, to differentiate the various isolates, a variety of
genetic methods have been established including the so-called
spoligotyping and IS6110 mycobacterial fingerprinting, in addi-
tion to the assessment of mycobacterial growth on selective media
and the morphology of colonies as well as conventional
biochemical assays.
We have studied the influence of MBL2 variants on suscepti-
bility and resistance to TB by comparing HIV-negative patients
with smear- and/or culture-positive pulmonary TB to unaffected
and unrelated control individuals in Ghana, West Africa.
Genotyping of MTBC isolates allowed to stratify in the association
study for the infecting MTBC strains and to search for a
contribution of pathogen variability.
Results
Genetic Association
A total of 2010 cases and 2346 controls were genotyped for the
three structural MBL2 exon 1 polymorphisms R52C (allele D),
G54D (allele B) and G57E (allele C) and three additional
polymorphisms at position 2550 (alleles H and L) and 2221
(alleles Y and X) in the promoter and at position +4 (alleles P and
Q) of the untranslated region of exon 1. Allele C was found at a
frequency of 0.33 in the entire study group. The D allele was not
detected at all, and allele B occurred at a frequency of 0.006 and,
therefore, was not considered in the statistical analyses. All variants
were in Hardy-Weinberg equilibrium both in the case and control
groups (Table 1).
Out of a total of 1567 mycobacterial isolates that were
genotyped, 1029 (65.7%) were M. tuberculosis Euro-American
(EUAM), and 56 (3.6%) belonged to the M. tuberculosis East-
African-Indian (EAI), Beijing or Delhi lineages. M. africanum was
identified in 472 (30.1%) isolates (M. africanum West African 1,
n=336; M. africanum West African 2, n=136), and 10 (0.6%) were
M. bovis. As the M. africanum and M. bovis lineages are closely
related phylogenetically by exhibiting both the RD9 deletion, they
were considered collectively in statistical analyses.
The frequencies of MBL2 variants found are shown in Table 2.
No significant differences were observed between cases and
controls when including all cases. However, stratification for the
major MTBC species of M. tuberculosis and M. africanum/M. bovis,
revealed that, assuming a recessive mode of inheritance, variant
G57E (allele C) occurred at a significantly lower frequency in
patients infected with M. africanum/M. bovis than in controls (OR
0.60, 95% CI 0.4–0.9, nominal P value [Pnom]=0.008), whereas
no evidence for an association was found for M. tuberculosis patients
alone. This distribution of genotypes implies that occurrence of the
MBL2 C allele is compatible with relative protection from TB
caused by M. africanum/M. bovis.
Haplotypes of promoter polymorphisms and the codon 57
variants (allele C) were inferred from unphased genotype data.
The presumably ancient MBL2 haplotype LYQC [5] (Table 3 and
Fig. 1), comprising the most common exon 1 variant in Africa
(allele C; our data and [18]), was strongly associated with
protection from infections caused by lineages of the M.
africanum/M. bovis species in a recessive model of inheritance
(corrected P value [Pcorr]=0.007 after 50 000 permutations; Max-
Stats global P value 0.035).
Binding of MBL to MTBC Isolates
Binding of MBL to glycosylated bacterial surfaces is a
prerequisite for complement activation and initiation of phagocy-
tosis. Flow cytometry was applied to study the interaction of MBL
with M. tuberculosis and M. africanum. Mycobacterial suspensions
were labelled with recombinant human MBL, biotinylated anti-
MBL antibody and Cy5-coupled streptavidin, and the percentage
of cells positive for MBL binding was assessed. For the three
clinical isolates (different IS6110 DNA fingerprints, data not
shown) of M. africanum (West African 2 10415/02, 10476/01 and
10514/01), approximately 35% percent of the population bound
MBL, whereas about 10% of the M. tuberculosis strains (Cameroon
5390/02, 5400/02, 1417/02) were positive for MBL binding.
Only five percent of cells of the laboratory M. tuberculosis strain
H37Rv were positive for MBL binding. In order to further
evaluate whether binding was mediated by C-type lectin
interactions, inhibition experiments using the calcium chelating
agent EDTA were performed. Binding of MBL was clearly
Table 1. MBL2 variants genotyped.
MBL2
variants rs # alleles
alternative
nomenclature localization
contig
(chromosome 10)
contig
position
chromosomal
position (bp) MAF (%)
HWE
cases P
HWE
controls P
2550 rs11003125 G/C H/L Promoter NG_008196.1 g.4447C.G 54202020 6.9 0.24 0.40
2221 rs7096206 C/G X/Y Promoter NG_008196.1 g.4776C.G 54201691 12.4 0.83 0.50
+4 rs7095891 A/G Q/P Exon 1 NG_008196.1 g.5000C.T 54201467 38.8 0.57 0.19
G54D rs1800450 A/G A/D Exon 1 NM_000242.2 c.161A.G 54201241 0.6 - -
G57E rs1800451 G/A A/C Exon 1 NM_000242.2 c.170G.A 54201232 33.1 0.75 0.46
rs, gene variant reference id; bp, base pairs; MAF, minor allele frequency; HWE, Hardy Weinberg equilibrium.
doi:10.1371/journal.pone.0020908.t001
MBL in TB
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divalent cation-dependent nature of MBL binding in this assay
format (Fig. 2 A). Representative histograms of MBL binding to
clinical isolates in the presence of Ca
2+ demonstrate a significant
increase in mean fluorescence intensity for the three M. africanum
strains when compared to four M. tuberculosis strains (P=0.034;
Fig. 2 B).
In conclusion, all M. africanum strains tested bound MBL
significantly better than did M. tuberculosis strains.
Discussion
Quantitative and functional MBL deficiencies resulting from
mutations in the promoter and the first exon of the MBL2 gene are
common throughout the human populations [18] (Fig. 1). We
found in a recessive mode of inheritance that the MBL2 low-
producer haplotype LYQC including the structural variant G57E
(allele C) was associated with protection from TB caused by M.
africanum/M. bovis but not from TB caused by M. tuberculosis.I n
addition to low plasma MBL levels associated with the L, Y and Q
promoter alleles, allele C is associated with lower amounts of the
functionally important MBL oligomers [4].
The observation in the genetic analysis was corroborated by
MBL binding studies that were performed with M. tuberculosis and
M. africanum isolates originating from Ghanaian TB patients and
with the laboratory strain H37Rv. The binding assays indicated
that all M. africanum isolates tested bound recombinant human
MBL to a greater extent than did M. tuberculosis isolates. Binding of
MBL to mycobacteria may mediate phagocytosis by their target
cell, the macrophage. Therefore, it may be concluded that a
decreased concentration and a functional impairment of MBL
caused by mutations of the LYQC haplotype might reduce
phagocytosis of mycobacteria by macrophages. Accordingly,
reduced uptake by macrophages could be one of a multitude of
events that contribute to resistance against TB. This conclusion is
supported by an experiment showing that a depletion of alveolar
macrophages increased resistance to tuberculosis in a murine
infection model indicating that uptake by macrophages serves the
survival and propagation of the mycobacteria rather than their
control by the host [19]. The observations made in this mouse
model are, however, not directly valid in human disease.
As MBL bound less effectively to M. tuberculosis in vitro one may
also hypothesize that impairment of MBL function is of less
relevance in TB caused by lineages of this species. Since MBL is
only one of several components which interact with mycobacterial
surface moieties, other mediators and cellular receptors might be
more important in the phagocytic uptake of M. tuberculosis [20].
In addition to MBL, the mannose receptor of macrophages
(MRC1) as well as receptors for complement (CR1, CR3, CR4),
surfactant protein A, macrophage scavenger receptors and CD14
all have been reported to be involved in pathogen-macrophage
interactions [21]. Thus, alternative mechanisms of uptake of
mycobacteria by macrophages exist and the responsiveness of
macrophages does not exclusively depend on recognition of
mycobacterial structures by MBL. It may, therefore, be concluded
that some or all of these receptors are more relevant in M.
tuberculosis than in M. africanum/M. bovis infections.
Genome analyses of several MTBC phylogenetic lineages have
revealed a multitude of variations indicating that the members of
the MTBC are far more genetically diverse than previously
thought [22]. Genes of various functional categories such as those
encoding constituents of metabolic pathways, membrane proteins
and virulence factors show remarkable variability, and the various
lineages are characterized by deep-tailed genomic deletions
Table 2. MBL2 genotype associations of all TB cases, cases infected with M. tuberculosis and cases infected with M. africanum,
compared with controls.
All TB
cases
M. africanum/M.
bovis cases
M. tuberculosis
Cases Controls
All cases vs.
controls
M. africanum/M. bovis
cases vs. controls
M. tuberculosis
cases vs controls
MBL2 variant genotype % % % % OR (CI) P OR (CI) Pnom OR (CI) Pnom
2550 CC 85.2 87.0 85.2 86.4 1 1 1
CG 14.4 12.6 14.4 13.2 1.09 [0.9–1.3] 0.36 0.93 [0.7–1.3] 0.66 1.08 [0.9–1.3] 0.51
GG 0.4 0.4 0.4 0.4 1.04 [0.4–2.9] 0.94 1.31 [0.3–6.2] 0.73 1.15 [0.3–3.9] 0.83
n=1843 n=446 n=972 n=2174
2221 GG 77.3 76.2 76.5 76.3 1 1 1
CG 21.3 21.8 22.4 22.3 0.93 [0.8–1.1] 0.34 0.96 [0.8–1.2] 0.77 0.99 [0.8–1.2] 0.94
CC 1.4 2.0 1.1 1.4 0.97 [0.6–1.7] 0.91 1.40 [0.7–3.0] 0.39 0.79 [0.4–1.6] 0.51
n=1859 n=449 n=982 n=2180
+4 AA 37.1 36.0 37.9 37.0 1 1 1
AG 47.1 47.9 46.7 48.7 0.95 [0.8–1.1] 0.48 0.99 [0.8–1.2] 0.91 0.93 [0.8–1.1] 0.37
GG 158 16.1 15.4 14.3 1.09 [0.9–1.3] 0.36 1.15 [0.8–1.5] 0.37 1.05 [0.8–1.3] 0.69
n=1953 n=478 n=1033 n=2230
G57E GG 46.7 48.9 46.9 44.8 1 1 1
AG 43.0 44.2 41.0 43.7 0.95 [0.8–1.1] 0.42 0.92 [0.7–1.1] 0.43 0.90 [0.8–1.1] 0.19
AA 10.2 6.9 12.1 11.5 0.90 [0.7–1.1] 0.33 0.58 [0.4–0.9] 0.006 1.07 [0.8–1.4] 0.60
recessive model 0.60 [0.4–0.9] 0.008
n=1894 n=477 n=1040 n=2236
Odds ratios (OR) and nominal P values (Pnom) adjusted for gender, age and ethnic groups by logistic regression.
CI, 95% confidence interval.
doi:10.1371/journal.pone.0020908.t002
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variation on the composition of cell walls of M. africanum/M. bovis
and M. tuberculosis is incompletely explored. In particular, it is not
clear whether the RD9 deletion, which is characteristic for M.
africanum lineages and for M. bovis, has an influence on the
composition of cell surface structures which might be relevant to
MBL binding. The binding characteristics of MBL to microbes are
also not fully understood. It has, however, been shown that MBL
variability affects its binding to mycobacteria [24,25]. Interesting-
ly, the TBd1 region, which is deleted in M. tuberculosis but not in M.
africanum/M. bovis lineages, comprises a number of genes encoding
membrane proteins which are thought to be responsible for lipid
transport and might be involved in determining the composition of
cell wall.
Differences in MBL binding properties have also been observed
in other bacterial infections [1,26]. Certain structures of capsular
Figure 1. MBL2 haplotype frequencies in different populations. 1, Argentina (Chiriguanos) [2]; 2, Argentina (Mapuche) [2]; 3, Greenland [2]; 4,
The Netherlands [47]; 5, Denmark [2]; 6, Spain [48], 7; Ghana (present study); 8, Mozambique [2]; 9, Kenya [2]; 10, Iran [49]; 11, China [13]; 12, Korea
[50]; 13, Japan [51]; 14, Australia [52].
doi:10.1371/journal.pone.0020908.g001
Table 3. MBL2 haplotype association comparing TB cases infected with M. africanum and controls.
Haplotype MBL2 SNPs
Score
statistic
1
Freq.
cases
2
Freq.
controls
2 P
3 Pcorr
4
2550 G/C.H/L 2221 C/G.X/Y +4A / G .Q/P G57E G/A.A/C
1L Y Q A 21.31 0.31 0.28 0.19 0.19
2L X P A 21.12 0.13 0.12 0.26 0.24
3H Y P A 20.53 0.07 0.07 0.60 0.52
4 L Y P A 0.78 0.20 0.19 0.43 0.43
5 L Y Q C 2.70 0.29 0.33 0.007 0.007
1Score statistic of the haplo.score software.
2Frequency; only haplotypes with a frequency .0.01 are shown.
3P values of haplotype-specific associations with a recessive mode of inheritance.
4Simulated haplotype-specific P values corrected for multiple testing by 50,000 permutations.
doi:10.1371/journal.pone.0020908.t003
MBL in TB
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binding [27] and bacterial cell wall components appear to be able
to mask MBL ligands (e.g. mannose, N-acetylglucosamine) or to
modify carbohydrate moieties or their densities on cell walls to
prevent MBL binding [28]. Taken together, considerable variation
exists in the strength of MBL binding to many microorganisms.
There is longstanding debate on whether MBL variability has
evolved through neutral evolution or as a result of natural selection
Figure 2. Comparison of MBL binding to M. africanum vs. M. tuberculosis strains by flow cytometry. Representative clinical isolates of M.
africanum and M. tuberculosis strains were processed for flow-cytometric analysis by labeling with recombinant human MBL, biotinylated anti-human
MBL antibody and Cy5-conjugated streptavidin). The percentage of positive cells for MBL binding was analyzed in triplicates for three different
clinical isolates of M. africanum and M. tuberculosis along with the laboratory strain H37Rv. Calcium dependence of binding was examined by the
addition of EDTA to the TBS/Ca
2+ buffer. Negative controls were processed in the absence of MBL. The mean percentage of positive cells of these
controls was subtracted from the corresponding percentages of positive cells of MBL-treated mycobacteria (A). Representative flow-cytometric
profiles of MBL binding to clinical isolates (depicted in A) in the presence of Ca
2+ (B). The Ghanaian MTBC strains used for the binding assays were M.
africanum West African 2 strains 10415/02, 10476/01, 10514/01 and M. tuberculosis Cameroon strains 5390/02, 5400/02 and 1417/02.
doi:10.1371/journal.pone.0020908.g002
MBL in TB
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dependent effects on the morbidity or mortality from infectious
diseases could not be identified [32]. Another study of febrile
adults did not find any correlation between microbial infections
and the MBL pathway of complement activation [33]. In contrast,
a plethora of case-control association studies has attributed a role
of MBL variability to infection phenotypes [34], and the common
belief now is that MBL2 variability has arisen as a consequence of
human contact with pathogenic microorganisms in diverse
geographic environments [18]. However, which balancing selec-
tion pressure, if any, might have established and preserved the
high frequencies of MBL variants, in particular that of allele C in
Africa, is not clear. It is also uncertain in how far mycobacterial
infections may have contributed to disseminate the variant MBL2
haplotypes and to shape human MBL diversity. It has repeatedly
been suggested that mycobacterial infections might have contrib-
uted significantly to maintain MBL variability [35,36]. The results
of our candidate gene study are in line with these suggestions and
argue for the emergence of MBL variability at least in part through
selective forces. It is, however, unlikely that mycobacteria alone
have exerted sustained selective pressure, as studies with infection
phenotypes caused by other pathogens have also yielded
significant genetic associations [4].
MBL variability appears to be of importance in infections with
mycobacteria which can bind great amounts of MBL as
documented in the present study. Apart from the mere genetic
aspect of the question addressed in our study it is now also a matter
of discussion whether deficiency of functional MBL may lead to
relative protection through impaired uptake of mycobacteria or
may cause increased susceptibility to TB [37]. There is, however,
considerable debate on whether great or low amounts of MBL have
any effect on the phenotype of MTBC infection and evidence on
this issue is ambiguous [7–13]. Notably, in all previous association
studies species and strain determination of MTBC agents and the
corresponding statistical stratifications were not performed.
Recent studies suggest that the MTBC has evolved in East
Africa approximately 40.000 years ago from a common ancestor,
addressed as M. prototuberculosis [22,38]. By human migration the
ancient M. africanum/M. bovis lineages, which first evolved from its
progenitor and are now characterized by the RD9 deletion, were
directly disseminated across sub-Saharan Africa. The more
modern M. tuberculosis lineages, characterized by the TBd1
deletion, moved out of Africa, spread initially over Europe and
Asia, and were re-introduced to Africa only centuries ago where
they are now part of the MTBC spectrum. This early geographical
segregation is believed to be the cause of lineage-specific
adaptation to distinct human host groups [22,23].
Theprotective MBL2haplotypeLYQC,which is virtually unique
to sub-Saharan Africa and occurs there at high frequencies, might
have been selected for, because it confers, with a significant odds
ratio, protection from clinical TB caused by M. africanum/M. bovis,
The question, however, namely that the MBL2 C allele occurs
across sub-Saharan Africa, while M. africanum appears still to be
largely restricted to the West African region [39], remains to be
solved.Indeed,M. africanum has been claimed to cause TB, although
as an uncommon pathogen, in other parts of Africa as well.
However, its occurrence outside of West Africa is not well
documented. As MBL is a molecule involved in the immune
response to a variety of pathogens, one explanation might be that
associations exist with phenotypes of other infectious diseases.
Lastly, the preliminary evidence that MBL2 variability in Africa,
in particular occurrence of the C allele, is associated with higher
Plasmodium falciparum parasite counts and more severe courses of
malaria [37,34] raises the question of TB-malaria counterbalancing
effects. Early selection of human genetic factors that provide
protection against the ancient species M. africanum [22,38] prior to
the more recent emergence of P. falciparum [40] in Africa might now
contribute to the deadly toll paid by falciparum malaria.
Materials and Methods
Ethics Statement, Patients and Controls
The study protocol was approved by the Committee on Human
Research, Publications and Ethics of The School of Medical
Sciences, Kwame Nkrumah University of Science and Technol-
ogy, Kumasi, Ghana, and the Ethics Committee of the Ghana
Health Service, Accra, Ghana. Blood samples were taken only
after a detailed explanation of the aims of the study, and consent
was obtained by signature or thumbprint.
Participants were consecutively enrolled in Ghana, West Africa,
between September 2001 and July 2004 at Korle Bu Teaching
Hospital in Accra, Komfo Anokye Teaching Hospital in Kumasi,
plus 15 additional hospitals and polyclinics in Accra and Kumasi
and at regional district hospitals. The case group included of 2010
HIV-negative individuals with smear-/culture-positive pulmonary
TB. Out of a total of 2346 control individuals, 1211 were
unrelated personal household contacts of cases and 1135 were
individuals from neighbouring houses or working contacts of cases.
Cases and controls belonged to the ethnic groups of Akan
(Ashanti, Fante, Akuapem), Ga-Adangbe, Ewe, all in the south of
Ghana, and several other ethnic groups from northern Ghana.
Patient phenotyping was based on the medical histories and the
documentation of major TB symptoms on structured question-
naires, physical examination, HIV-1/2 antibody status testing
(Capillus, Trinity Biotech, Bray, Co Wicklow, Ireland) and
posterior-anterior chest X-rays. The microbiological diagnosis
was made by Ziehl-Neelsen staining of two independent sputum
smears and culturing of M. tuberculosis on Lo ¨wenstein-Jensen agar
with subsequent determination of mycobacterial species, lineages
and fine-typing of mycobacterial genotypes. Cases were HIV-
negative and had radiological lesions characteristic of pulmonary
TB. All patients were treated in the framework of the DOTS
programme (Directly Observed Treatment Short-Course Strategy)
organized by the National Tuberculosis Programme of Ghana.
Study participants belonged to the following ethnic groups (cases/
controls): Akan including Ashanti, Fante, Akuapem (63.6%/
59.1%), Ga-Adangbe (14.5%/19.8%), Ewe (7.1%/9.3%) and
ethnic groups of northern Ghana including Dagomba, Sissala,
Gonja, and Kusasi (12.9%/10.4%). The proportions of ethnicities
among patients and controls did not differ significantly.
Disclosure of HIV test results was dependent on the prior
documentation of the willingness of the study participants to be
informed and included for HIV-positive patients their prompt
referral to counseling and treatment provided by the Ghanaian
AIDS Control Programme.
The characterisation of controls consisted of a medical history
and clinical examination, chest X-ray and a tuberculin skin test
(Tuberculin Test PPD Me ´rieux, bioMe ´rieux, Nu ¨rtingen, Ger-
many). The controls had no radiological signs of actual or previous
pulmonary TB. Further details of the recruitment procedure and
the composition of the study group including the distribution of
ethnicities have been described previously [41,42].
HIV Testing
For HIV-1/-2 testing of TB cases, a capillary test system
(Capillus, Trinity Biotech, Bray, Co Wicklow, Ireland) was
applied. HIV positivity was confirmed by the Organon Teknika
Vironostika HIV-1/-2 EIA system (Organon Teknika, Turnhout,
MBL in TB
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patients were excluded from further genetic analyses.
Genotyping of Genetic Variants
After DNA extraction from peripheral blood by a magnetic
separation technology (AGOWAH mag Maxi DNA Isolation Kit,
Berlin, Germany) according to the manufacturer’s instructions.
Genotyping of the three structural MBL2 variants in exon 1 at
codons 52, 54 and 57 (allele A=wild-type, alleles B, C, D=variant
alleles) were performed using a high-throughput pyrosequencing
assay (http://www.pyrosequencing.com/) at the Max-Delbru ¨ck-
Center for Molecular Medicine, Berlin, Germany. Promoter
variants at nt positions 2550, 2221 and +4 were analyzed by
dynamic allele-specific hybridization with fluorescence resonance
energy transfer (FRET) in a LightTyper device (Roche). Primer
pairs and sensor/anchor oligonucleotides for LightTyper-based
MBL2 promoter genotyping are listed in Table 4.
Typing of MTBC Agents
MTBC isolates were cultured on solid Lo ¨wenstein-Jensen media
and shipped to the German National Reference Centre for
Mycobacteria (Borstel, Germany) for minute analyses of biochem-
ical, growth and molecular characteristics. Molecular differentia-
tion of 1567 mycobacterial isolates included resistance typing,
spoligotyping, IS6110 fingerprinting and typing of the pks1/15
deletion as described previously [43–46]. Mycobacterial strains
were for further stratification grouped according to the major
phylogenetic lineages [38].
The stepwise procedure of typing of mycobacteria included an
initial cluster analysis of IS6110 fingerprinting data and lineage
identification according to specific spoligotype signatures. Assign-
ment of lineages was based on the MIRU-VNTRplus webpage
(www.miru-vntrplus.org) and a reference strain collection using the
Bionumerics 5.1 software (Applied Maths, Sint-Martens-Latem,
Belgium). Classification was confirmed by random selection of 20
strains of each group and testing for the presence of lineage-
specific deletions as follows: pks1/15 for M. tuberculosis Euro-
American, region of difference (RD) 239 for M. tuberculosis East
African Indian (EAI), RD9 and RD711 for M. africanum West
African 1, RD9 and RD702 for M. africanum West African 2, and
RD9 and RD4 for M. bovis. All M. tuberculosis strains with
ambiguous lineage identification were confirmed as belonging to
the Euro-American lineage by identifying the presence of the pks1/
15 7 bp deletion. Deletion typing was performed using protocols
available at the MIRU-VNTRplus webpage.
MBL Binding Assay
For binding experiments, M. tuberculosis aliquots were thawed,
spun at 22606 g for 10 min and the pellet was resuspended in
TBS buffer (150 mM NaCl, 20 mM TRIS, pH 7.4). To ensure
proper dispersion of mycobacteria, 1 ml of the suspension was
drawn through a nonpyrogenic needle and aliquots of 1610
7
mycobacteria were processed for MBL binding. After centrifuga-
tion the pellet was resuspended in 50 ml TBS buffer supplemented
with 5 mM Ca
2+ (TBS/Ca
2+) and 5 mg/ml recombinant human
MBL (R&D Systems, Wiesbaden, Germany) followed by an
incubation at 37uC for 30 min. Cells were washed by adding
100 ml TBS/Ca
2+ buffer and centrifuged before resuspension in
50 ml TBS/Ca
2+ containing 2.5 mg/ml biotinylated anti-human
MBL antibody (R&D Systems, Wiesbaden, Germany) and
incubation at 37uC for 30 min. After washing by addition of
TBS/Ca
2+ and centrifugation mycobacteria were resuspended in
50 ml TBS/Ca
2+ supplemented with Cy5-conjugated streptavidin
(Jackson Immunoresearch Europe Ltd., Newmarket, Suffolk, UK)
and incubated at 37uC for 30 min. Cells were washed and
prepared for flow cytometry by resuspending in 300 ml of TBS/
Ca
2+ buffer and fluorescence intensity was measured on a
FACSCalibur
TM cytometer at medium flow rates (BD Biosciences,
Heidelberg, Germany). The specificity of MBL binding to the
clinical isolates was investigated by using the inhibitor EDTA.
15 mM EDTA was added to the TBS/Ca
2+ buffer 10 min prior to
the incubation with MBL. Negative controls comprising myco-
bacteria processed in the same way but in the absence of MBL
were included for every clinical isolate and binding condition.
The data were analyzed using CellQuest Pro software (BD
Biosciences, Heidelberg, Germany). In order to discriminate the
mycobacterial population from nonbacterial particles a gate was
defined in the forward (size) and side scatter (granularity) which
was confirmed by mycobacteria labelled with an anti-Mycobacterium
tuberculosis antibody (abcam, Cambridge, UK). Data were
expressed as percentage of cells positive for MBL binding. Non-
specific binding was excluded by subtracting the mean percentage
of positive cells in the negative controls (w/o MBL) from the
respective percentage of positive cells in MBL-treated mycobac-
teria. Data are representative of four independent experiments
which were each performed as triplicate measurements.
Databases, Statistics
Demographic data, self-reported signs and symptoms docu-
mented on structured questionnaires as well as laboratory results
were double-entered into a Fourth Dimension database (San Jose,
Table 4. Primer Pairs and sensor/anchor oligonucleotides for LightTyper-based MBL2 genotyping.
MBL2 Primer oligonucleotides Sensor/Anchor oligonucleotides
2550 F-AGAAAGTAGAGAGGTATTTAGCAC S-GGCAAGCCTGTCTAAAACACCAAG-6-Fam
R-GTGATCCAAAGAGGAAGGTC A-Cy5-GGAAGCAAACTCCAGTTAATTCTGGGCTGGG-phosphate
2221 F-CTCATTCTCATTCCCTAAGCTAAC S-GCCACCGAAAGCATGTTTATAGTCT-6-Fam
R-AACAAAGGTAGGCACTATGAT A-Cy5-CCAGCAGCAACGCCAGGTGTC-phosphate
+4 F-GAGAAGGAGAGGGAGTGAT S-Cy5-GCTCGGTAAATATGTGTTCATTAACTGAGATTAAC-phosphate
R-GTGTCACAAGGAATGTTTACTTT A-CTGCACCCAGATTGTAGGACAGAGGGC-6-Fam
p.G54D F-GTGGCAGCGTCTTACTC S-TGGGCGTGATGACACCAAGGAAGA-6-Fam
p.G57E R-TTCCTCTGGAAGGTAAAGAATTG A-Cy5-AAGGGGGAACCAGGTACGTGTTGGG-phosphate
F, forward primer; R, reverse primer; S, sensor oligonucleotide; A, anchor oligonucleotide; 6–Fam, 6–carboxyfluorescein; Cy5, corresponding to the Roche fluorophore LC
Red 640; synthesized by biomers.net GmbH, Ulm, Germany.
doi:10.1371/journal.pone.0020908.t004
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Data were locked before using them in a pseudonymized form for
statistical analyses. Power calculations were performed with the
public CATS software (http://www.sph.umich.edu/csg/abecasis/
CaTS/).
Multivariate logistic regression analyses were calculated for
different models to determine odds ratios (OR) for allele and
genotype distributions (STATA 10.0 software; Stata Corporation,
College Station, TX, USA). As age, sex and ethnicity were significant
confounders, they were appropriately adjusted for. Analyses of allele
distributions and Hardy-Weinberg equilibria (HWE) were calculated
with a public STATA module (www-gene.cimr.cam.ac.uk/clayton/
software/stata/genassoc; David Clayton, Cambridge, UK).
Haplotype frequencies were estimated and compared using the
haplo.score module of the haplo.stats package (http://cran.r-
project.org/web/packages/haplo.stats/index.html). Max-Stats P
values obtained testing an overall association between haplotypes
and the phenotype corrected for multiple testing by 50,000
permutations.
Differences in the MBL binding properties were calculated
using the non-parametric Kruskal-Wallis test.
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